Last Updated

22 May 2020

Attractive Targeted Sugar Bait (ATSB) Trial in Mali

Objectives

The main aim of this study is to establish the efficacy and contribution of the attractive targeted sugar baits (ATSBs) for controlling malaria transmission where Anopheles gambiae sensu lato (s.l.) and Anopheles Funestus are the major vectors for malaria.

Principal Investigator
Rationale and Abstract

Vectors in Sub-Saharan Africa (SSA) are often anthropophagic and anthropophilic, and exhibit indoor biting and indoor resting behavior. Highly effective interventions against vectors have been developed and implemented at scale (e.g., indoor Residual Spraying of Insecticides [IRS] and Long Lasting Insecticide-treated Nets [LLINs]). While these interventions have contributed importantly to the reduction of malaria transmission and disease (68% and 11% respectively), none of them target outdoor-biting g and outdoor-resting mosquitoes. Given the increase in resistance to current generation of insecticides and the behavioral plasticity of vectors that results in continued malaria transmission despite high coverage of LLINs or IRS, there is a need for interventions that can supplement and complement LLINs and IRS by killing mosquitoes outside houses using other biologic mechanisms (e.g., targeting sugar feeding behavior). Attractive Target Sugar Baits (ATSBs) that kill mosquitoes through the ingestion of the toxicant dinotefuran (and possibly by other ingestion toxicants that are effective when ingested) potentially fill the need for outdoor interventions with novel killing effects.

Study Design

Allocation: Randomized
Intervention Model: Factorial Assignment
Intervention Model Description:
An open-label two-arm cluster randomized controlled trial (CRCT) design will be used comparing ATSB + LLINS vs LLINS alone (standard of care). A cluster trial design is indicated given the intended community-level effect of ATSBs on malaria transmission. Universal LLIN coverage will be ensured in both arms prior to start of the study and will serve as the standard of care. Arm 1 will receive ATSBs for two years. Arm 2 will receive the standard of care of universal LLIN coverage.

ClinicalTrials.gov Identifier: NCT04149119

Date

2021 May - 2023 Jun

Funding Details

Project Site